Citations

Clear

14 citation(s) found for "Secreto, Frank".

iPS Cell–Derived Cardiogenicity is Hindered by Sustained Integration of Reprogramming Transgenes
Martinez‐Fernandez, Almudena , Reyes, Santiago , Alekseev, Alexey E., Secreto, Frank J., Pérez-Terzic, Carmen, Beraldi, Rosanna, Sung, Hoon‐Ki , Nagy, András , Secreto, Frank, Nelson, Timothy J. , Terzic, André

Mayo Clinic

Circulation: Cardiovascular Genetics | July 31, 2014 | Volume: 7 | Issue: 5 | Pages: 667-676

10.1161/circgenetics.113.000298 | PMID 25077947 Get It

Background—Nuclear reprogramming inculcates pluripotent capacity by which de novo tissue differentiation is enabled. Yet, introduction of ectopic reprogramming factors may desynchronize natural developmental schedules. This study aims to evaluate the effect of imposed transgene load on the cardiogenic competency of induced pluripotent stem (iPS) cells.Methods and Results—Targeted inclusion and exclusion of reprogramming transgenes (c-MYC,KLF4,OCT4, andSOX2) was achieved using a drug-inducible and removable cassette according to the piggyBac transposon/transposase system. Pulsed transgene overexpression, before iPS cell differentiation, hindered cardiogenic outcomes. Delayed in counterparts with maintained integrated transgenes, transgene removal enabled proficient differentiation of iPS cells into functional cardiac tissue. Transgene-free iPS cells generated reproducible beating activity with robust expression of cardiac α-actinin, connexin 43, myosin light chain 2a, α/β-myosin heavy chain, and troponin I. Although operational excitation–contraction coupling was demonstrable in the presence or absence of transgenes, factor-free derivatives exhibited an expedited maturing phenotype with canonical responsiveness to adrenergic stimulation.Conclusions—A disproportionate stemness load, caused by integrated transgenes, affects the cardiogenic competency of iPS cells. Offload of transgenes in engineered iPS cells ensures integrity of cardiac developmental programs, underscoring the value of nonintegrative nuclear reprogramming for derivation of competent cardiogenic regenerative biologics.
Constitutive activation of STAT5A and STAT5B regulates IgM secretion in Waldenström's macroglobulinemia
Hodge, Lucy S. , Ziesmer, Steven C., Yang, Zhi‐Zhang, Secreto, Frank J., Novak, Anne J. , Ansell, Stephen M.

Mayo Clinic

Blood | December 12, 2013 | Volume: 123 | Issue: 7 | Pages: 1055-1058

10.1182/blood-2013-08-521963 | PMID 24335105 Get It

Key Points STAT5 is constitutively phosphorylated in malignant B cells obtained from patients with Waldenström's macroglobulinemia. Inhibition of STAT5 signaling significantly decreases IgM production and may be useful therapeutically for patients with high IgM levels.
IL-21 in the bone marrow microenvironment contributes to IgM secretion and proliferation of malignant cells in Waldenstrom macroglobulinemia
Hodge, Lucy S. , Ziesmer, Steve, Secreto, Frank J., Novak, Anne J. , Ansell, Stephen M. , Yang, Zhi Zhang , Gertz, Morie A.

Mayo Clinic

Blood | September 15, 2012 | Volume: 120 | Issue: 18 | Pages: 3774-3782

10.1182/blood-2012-03-419440 | PMID 22976953 Get It

Abstract Cytokines within the tumor microenvironment play an important role in supporting the growth and survival of B-cell malignancies. One such cytokine, IL-21, promotes the growth of myeloma and Hodgkin lymphoma cells while inducing apoptosis in chronic lymphocytic leukemia. However, the biologic significance of IL-21 has not been examined in Waldenstrom macroglobulinemia (WM), a B-cell lymphoma characterized by elevated serum IgM and a lymphoplasmacytic bone marrow infiltrate. We report here on the presence of IL-21 in the bone marrow of patients with WM and have identified activated T cells as the source of this cytokine. We readily detected the IL-21 receptor on malignant WM B cells and show that IL-21 significantly increases both IgM secretion and cellular proliferation of these cells with no effect on viability. IL-21 rapidly induces phosphorylation of STAT3 in WM cells, and treatment of the WM cell line MWCL-1 with a STAT3 inhibitor abolished the IL-21–mediated increases in cellular proliferation and IgM secretion. IL-21 also increased the expression of known STAT3 targets involved in B-cell differentiation, including BLIMP-1, XBP-1, IL-6, and IL-10. Overall, our data indicate that IL-21 in the bone marrow microenvironment significantly affects the biology of WM tumor cells through a STAT3-dependent mechanism.
t(X;14)(p11;q32) in MALT lymphoma involving GPR34 reveals a role for GPR34 in tumor cell growth
Ansell, Stephen M. , Akasaka, Takashi , McPhail, Ellen D. , Braggio, Esteban , Price-Troska, Tammy, Ziesmer, Steven C., Secreto, Frank J., Fonseca, Rafaël , Dyer, Martin J.S. , Cerhan, James R. , Novak, Anne J. , McPhail, Ellen Darcy , Manske, Michelle K. , Gupta, Mamta , Law, Mark E. , Witzig, Thomas E. , Doǧan, Ahmet , Cerhan, James R , Braggio, Esteban , Fonseca, Rafael

Mayo Clinic

Blood | September 11, 2012 | Volume: 120 | Issue: 19 | Pages: 3949-3957

10.1182/blood-2011-11-389908 | PMID 22966169 Get It

AbstractGenetic aberrations, including trisomies 3 and 18, and well-defined IGH translocations, have been described in marginal zone lymphomas (MZLs); however, these known genetic events are present in only a subset of cases. Here, we report the cloning of an IGH translocation partner on chromosome X, t(X;14)(p11.4;q32) that deregulates expression of an poorly characterized orphan G-protein–coupled receptor, GPR34. Elevated GPR34 gene expression was detected independent of the translocation in multiple subtypes of non-Hodgkin lymphoma and distinguished a unique molecular subtype of MZL. Increased expression of GPR34 was also detected in tissue from brain tumors and surface expression of GPR34 was detected on human MZL tumor cells and normal immune cells. Overexpression of GPR34 in lymphoma and HeLa cells resulted in phosphorylation of ERK, PKC, and CREB; induced CRE, AP1, and NF-κB–mediated gene transcription; and increased cell proliferation. In summary, these results are the first to identify a role for a GPR34 in lymphoma cell growth, provide insight into GPR34-mediated signaling, identify a genetically unique subset of MZLs that express high levels of GPR34, and suggest that MEK inhibitors may be useful for treatment of GPR34-expressing tumors.